How to fool a wonder drug: truncate and dimerize

Authors list

Miriam Molina Arcas Julian Downward
Scroll for detail on labs, facilities & authors

Abstract

In a recent paper, Poulikakos et al. describe a new and potentially common mechanism whereby melanomas develop resistance to the BRAF inhibitor vemurafenib by expressing truncated forms of BRAF(V600E) that can dimerize in the absence of activated RAS. Will it be possible to block this with improved BRAF inhibitor design?

Journal details

Journal Cancer Cell
Volume 21
Issue number 1
Pages 7-9
Publication date

Full text links

Publisher website (DOI) 10.1016/j.ccr.2011.12.017
Europe PubMed Central 22264784
Pubmed 22264784

Keywords

Type of publication